

01 March 2024

Drugs Treatments Relating to Migraine

A. How many patients have been treated with the following drugs in the past 4 months:

- Atogepant (Aquipta) – any disease
 - Erenumab (Aimovig) - any disease
 - Eptinezumab (Vyepiti) – any disease
 - Fremanezumab (Ajovy) - any disease
 - Galcanezumab (Emgality) - any disease
 - Rimegepant (Vydura) – any disease
 - Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY
- The trust does not at present have an electronic prescribing system and is unable to provide this information to patient level.

B. How many patients have you treated in the last 4 months for chronic migraine (15+ headache days per month) and episodic migraine (4-15 headache days per month) with the following drugs:

Drugs	Chronic Migraine (15+ headache days per month)	Episodic Migraine (4-15 headache days per month)
Atogepant	0	0
Erenumab	0	0
Eptinezumab	0	0
Fremanezumab	0	0
Galcanezumab	32	0
Rimegepant	4	4
Botulinum Toxin	130	0

C. Does the trust actively initiate a treatment pause (usually at 12 months) of anti-CGRP (calcitonin gene-related peptide inhibitors) migraine treatment with the aim to re-start treatment if the patient continues to fit the criteria (Yes/No)?

- Yes where possible